Back to Report Store Home

Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits

  • Published: Jun-2012
  • Report Code: GBIHC237MR
  • Report Format: pdf

Description

GBI Research, the leading business intelligence provider, has released its new report “Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits”. It analyzes the overall Supply Chain Management (SCM) scenario and provides profiles of the leading participants in the pharmaceutical supply chain in the US. The report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The top three wholesalers in the US, AmerisourceBergen Corporation, Cardinal Health and McKesson Corporation, accounted for 86.7% of the overall US pharmaceutical market in 2011 and combined revenue of $295.2 billion. Various supply chain models are followed across the pharmaceutical industry, such as traditional wholesaler models, limited distribution models and direct distribution models. Pharmaceutical companies are now focusing on supply chains as a value-adding process rather than viewing them as a money drain, which was the scenario in the past. Managing a supply chain is a complicated task, as there are a number of issues that can affect performance and disrupt product and information flow.

Counterfeits have emerged as the greatest threat to the smooth functioning of the supply chain in the US. The recent case of fake Avastin entering the legitimate supply chain has raised concerns over administrative abilities, and the Food and Drug Administration (FDA) has taken numerous steps to track and trace counterfeits. The state of California has implemented the E-pedigree model and announced implementation deadlines for wholesalers, manufacturers and pharmacies. In 2009, 1,742 drugs were recalled by FDA, for a range of reasons such as quality of raw materials, defective labeling, packaging issues and contaminated products. Over-the-counter (OTC) and generic products account for the most recalls.

Scope

  • Segmentation of the pharmaceutical supply industry in terms of major components such as manufacturer, wholesaler and pharmacy

  • Key issues facing the pharmaceutical supply chain in the US

  • Analysis of strategies adopted by pharmaceutical manufacturers and wholesalers to remain competitive

  • Key parameters which are considered for rejuvenating the existing supply chain

  • Profiles of key pharmaceutical supply chain management companies

  • Emerging technologies being developed for anti-counterfeit operations.

Reasons To Buy

  • Understand the existing market scenario

  • Analyze the requirements for regulatory compliance for pharmaceutical supply chain management

  • Pinpoint key uncertainties facing the pharmaceutical supply chain in the US

  • Develop strategies for implementing lean technology in the pharmaceutical supply chain

  • Develop risk mitigation strategies

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards